Aerovate Therapeutics Files 8-K
Ticker: JBIO · Form: 8-K · Filed: Apr 21, 2025 · CIK: 1798749
| Field | Detail |
|---|---|
| Company | Aerovate Therapeutics, INC. (JBIO) |
| Form Type | 8-K |
| Filed Date | Apr 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-events, disclosure
TL;DR
Aerovate Therapeutics filed an 8-K on April 21, 2025, detailing events from April 16, 2025, including votes and disclosures.
AI Summary
Aerovate Therapeutics, Inc. filed an 8-K on April 21, 2025, reporting on events that occurred on April 16, 2025. The filing indicates matters submitted to a vote of security holders, a Regulation FD disclosure, and other events, along with financial statements and exhibits. The company is incorporated in Delaware and headquartered in Waltham, Massachusetts.
Why It Matters
This 8-K filing provides updates on significant corporate events and disclosures for Aerovate Therapeutics, Inc., which could impact investor understanding of the company's current status and future direction.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting on corporate events and disclosures, not indicating any immediate financial distress or significant operational changes.
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Waltham, Massachusetts (location) — Principal Executive Offices
- April 16, 2025 (date) — Earliest event reported
- April 21, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Aerovate Therapeutics' security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not elaborated upon in the provided text.
What is the nature of the Regulation FD Disclosure mentioned in the filing?
The filing acknowledges a Regulation FD Disclosure, but the content of this disclosure is not detailed in the provided excerpt.
What are the 'Other Events' that Aerovate Therapeutics is reporting?
The filing lists 'Other Events' as a category of information being reported, but the specific events are not described in the provided text.
When was Aerovate Therapeutics, Inc. incorporated and where are its principal executive offices located?
Aerovate Therapeutics, Inc. was incorporated in Delaware and its principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, Massachusetts.
What is the Commission File Number and IRS Employer Identification Number for Aerovate Therapeutics, Inc.?
The Commission File Number for Aerovate Therapeutics, Inc. is 001-40544, and its IRS Employer Identification Number is 83-1377888.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 21, 2025 regarding Aerovate Therapeutics, Inc. (JBIO).